Forest Labs

Forest Labs
Share

Forest Labs

 •  March 8

- Application Seeks to Expand VRAYLAR Label to Include Phase 3 Clinical Data for the Maintenance Treatment of Schizophrenia- DUBLIN, Ireland, March 8, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company's...

Forest Labs

 •  January 30

- New clinical data for AVYCAZ demonstrates efficacy in cUTI patients including those with infections due to resistant Gram-negative pathogens -
- Responding to the urgent public health threat posed by certain CRE - DUBLIN, Jan. 30, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S....

Forest Labs

 •  October 29, 2016

DUBLIN, Oct. 29, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company committed to research informing the treatment of infectious diseases, presented new data identifying hospitalized patients with serious infections due to Enterobactericaeae who are at greater risk for having carbapenem-resistant...

Forest Labs

 •  October 27, 2016

-- Allergan and Rhythm Holding Announce Acquisition Following Positive Results for Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis -- DUBLIN and BOSTON, Oct. 27, 2016 /PRNewswire/ -- Allergan plc. (NYSE: AGN), a leading global pharmaceutical company and Rhythm Holding Company, LLC, which owns Motus Therapeutics, Inc. a...

Forest Labs

 •  October 25, 2016

Profile experts share insider tips for better social profile photos, while TV campaign addresses "double chin" DUBLIN, Oct. 25, 2016 /PRNewswire/ -- Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or "double chin."1 And with social media profile images becoming more important than...

Forest Labs

 •  October 24, 2016

DUBLIN, Oct. 24, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company committed to improving outcomes and meeting critical needs in infectious diseases, will present new data from its anti-infectives portfolio as a part of 23 presentations at the upcoming IDWeek 2016, taking place Oct. 26-30, 2016, in New Orleans....

Forest Labs

 •  October 17, 2016

DUBLIN and FORT WASHINGTON, Pa., Oct. 17, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced that the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), has...

Forest Labs

 •  October 11, 2016

- Application Seeks to Expand AVYCAZ Label to Include Phase 3 Clinical Data for the Treatment of Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis - DUBLIN, Oct. 11, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted...

Forest Labs

 •  October 7, 2016

New Survey to Determine Awareness and Impact of Cervical Dystonia on Patients and Their Families DUBLIN and CHICAGO, Oct. 7, 2016 /PRNewswire/ -- Allergan and the Dystonia Medical Research Foundation (DMRF) are proud to continue their long-standing partnership in support of dystonia patients by conducting a survey to evaluate awareness of cervical...

Forest Labs

 •  October 3, 2016

-- MEDI2070 in Development for the Potential Treatment of Crohn's Disease and Ulcerative Colitis -
-- MEDI2070 Next-Generation IL-23-Only Targeted Therapy for Crohn's Disease, Ulcerative Colitis; Potentially Providing Broader Therapeutic Window than IL12/23 Targeting Therapies -
-- Expands Allergan's Innovative Gastroenterology Pipeline into...